A role for lysophosphatidic acid and sphingosine 1-phosphate in the pathogenesis of systemic sclerosis.

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

Systemic sclerosis (SSc) is a complex fibrosing autoimmune disease that has variable clinical manifestations and morbidity/mortality secondary to organ damage due to vasculopathy and/or fibrosis. Initial events in the pathogenesis are manifested by fibroproliferative vasculopathy that compromises delivery of blood to critical organs. There is evidence of autoimmunity early in the disease which persists and is accompanied by fibrotic processes that leave large accumulations of collagen and other matrix components in the intima of blood vessels and extracellularly in the connective tissue of organs affected by the disease. It has recently been realized that the lysophospholipids -- lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P), which are elevated in sera of SSc patients, are capable of producing many of the abnormalities observed in the vasculature, immune system, and connective tissue of patients with this disease. This article reviews key abnormalities of the vasculature, immune system, and connective tissue in SSc that could be mediated by LPA/S1P.

Original languageEnglish (US)
Pages (from-to)161-167
Number of pages7
JournalDiscovery medicine
Volume10
Issue number51
StatePublished - Jan 1 2010

Fingerprint

Systemic Scleroderma
Connective Tissue
Immune System
Lysophospholipids
Autoimmunity
Autoimmune Diseases
Blood Vessels
Fibrosis
Collagen
Morbidity
Mortality
Serum
lysophosphatidic acid
sphingosine 1-phosphate

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

A role for lysophosphatidic acid and sphingosine 1-phosphate in the pathogenesis of systemic sclerosis. / Pattanaik, Debendra; Postlethwaite, Arnold.

In: Discovery medicine, Vol. 10, No. 51, 01.01.2010, p. 161-167.

Research output: Contribution to journalReview article

@article{d761b9d552e641598e2249483986657a,
title = "A role for lysophosphatidic acid and sphingosine 1-phosphate in the pathogenesis of systemic sclerosis.",
abstract = "Systemic sclerosis (SSc) is a complex fibrosing autoimmune disease that has variable clinical manifestations and morbidity/mortality secondary to organ damage due to vasculopathy and/or fibrosis. Initial events in the pathogenesis are manifested by fibroproliferative vasculopathy that compromises delivery of blood to critical organs. There is evidence of autoimmunity early in the disease which persists and is accompanied by fibrotic processes that leave large accumulations of collagen and other matrix components in the intima of blood vessels and extracellularly in the connective tissue of organs affected by the disease. It has recently been realized that the lysophospholipids -- lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P), which are elevated in sera of SSc patients, are capable of producing many of the abnormalities observed in the vasculature, immune system, and connective tissue of patients with this disease. This article reviews key abnormalities of the vasculature, immune system, and connective tissue in SSc that could be mediated by LPA/S1P.",
author = "Debendra Pattanaik and Arnold Postlethwaite",
year = "2010",
month = "1",
day = "1",
language = "English (US)",
volume = "10",
pages = "161--167",
journal = "Discovery medicine",
issn = "1539-6509",
publisher = "Discovery Medicine",
number = "51",

}

TY - JOUR

T1 - A role for lysophosphatidic acid and sphingosine 1-phosphate in the pathogenesis of systemic sclerosis.

AU - Pattanaik, Debendra

AU - Postlethwaite, Arnold

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Systemic sclerosis (SSc) is a complex fibrosing autoimmune disease that has variable clinical manifestations and morbidity/mortality secondary to organ damage due to vasculopathy and/or fibrosis. Initial events in the pathogenesis are manifested by fibroproliferative vasculopathy that compromises delivery of blood to critical organs. There is evidence of autoimmunity early in the disease which persists and is accompanied by fibrotic processes that leave large accumulations of collagen and other matrix components in the intima of blood vessels and extracellularly in the connective tissue of organs affected by the disease. It has recently been realized that the lysophospholipids -- lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P), which are elevated in sera of SSc patients, are capable of producing many of the abnormalities observed in the vasculature, immune system, and connective tissue of patients with this disease. This article reviews key abnormalities of the vasculature, immune system, and connective tissue in SSc that could be mediated by LPA/S1P.

AB - Systemic sclerosis (SSc) is a complex fibrosing autoimmune disease that has variable clinical manifestations and morbidity/mortality secondary to organ damage due to vasculopathy and/or fibrosis. Initial events in the pathogenesis are manifested by fibroproliferative vasculopathy that compromises delivery of blood to critical organs. There is evidence of autoimmunity early in the disease which persists and is accompanied by fibrotic processes that leave large accumulations of collagen and other matrix components in the intima of blood vessels and extracellularly in the connective tissue of organs affected by the disease. It has recently been realized that the lysophospholipids -- lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P), which are elevated in sera of SSc patients, are capable of producing many of the abnormalities observed in the vasculature, immune system, and connective tissue of patients with this disease. This article reviews key abnormalities of the vasculature, immune system, and connective tissue in SSc that could be mediated by LPA/S1P.

UR - http://www.scopus.com/inward/record.url?scp=79953661423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953661423&partnerID=8YFLogxK

M3 - Review article

C2 - 20807477

AN - SCOPUS:79953661423

VL - 10

SP - 161

EP - 167

JO - Discovery medicine

JF - Discovery medicine

SN - 1539-6509

IS - 51

ER -